GlaxoSmithKline Pharmaceuticals Limited Stock NSE India S.E.
Stocks
GLAXO
INE159A01016
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,202.80 INR | +3.78% |
|
+0.37% | -10.95% |
| Market Cap | 373B 3.94B 3.4B 3.13B 2.94B 5.52B 5.58B 36.98B 14.41B 183B 14.8B 14.49B 633B | P/E Ratio 2027 * |
32.7x | P/E Ratio 2028 * | 29x |
|---|---|---|---|---|---|
| Enterprise Value | 373B 3.94B 3.4B 3.13B 2.94B 5.52B 5.58B 36.98B 14.41B 183B 14.8B 14.49B 633B | EV / Sales 2027 * |
8.89x | EV / Sales 2028 * | 8.03x |
| Free-Float |
24.36% | Yield 2027 * |
1.34% | Yield 2028 * | 1.34% |
Last Transcript: GlaxoSmithKline Pharmaceuticals Limited
| 1 day | +3.78% | ||
| 1 week | +0.37% | ||
| Current month | -0.33% | ||
| 1 month | -9.68% | ||
| 3 months | -8.33% | ||
| 6 months | -14.80% | ||
| Current year | -10.95% |
| 1 week | 2,088.1 |  | 2,208.7 |
| 1 month | 2,088.1 | | 2,440 |
| Current year | 2,088.1 | | 2,719.8 |
| 1 year | 2,088.1 | | 3,500 |
| 3 years | 1,377.25 | | 3,515.7 |
| 5 years | 1,227 | | 3,515.7 |
| 10 years | 962.65 | | 3,515.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 56 | 01/12/2022 |
Ronojit Biswas
DFI | Director of Finance/CFO | - | 01/04/2026 |
Shalini Menon
CTO | Chief Tech/Sci/R&D Officer | - | 08/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Subesh Williams
BRD | Director/Board Member | 64 | 07/04/2017 |
Renu Sud Karnad
CHM | Chairman | 73 | 01/04/2019 |
| Director/Board Member | 59 | 18/05/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.78% | +0.37% | - | - | 3.81B | |
| -0.61% | -1.94% | +39.00% | +150.72% | 1,007B | |
| -0.20% | -0.77% | +51.51% | +43.20% | 567B | |
| +0.40% | -1.31% | +16.56% | +60.47% | 392B | |
| -1.18% | +2.29% | +24.04% | +16.53% | 328B | |
| -0.43% | +1.12% | +24.21% | +31.89% | 277B | |
| +0.64% | -2.55% | +22.80% | +12.69% | 275B | |
| -1.86% | +4.01% | -43.73% | -49.21% | 196B | |
| -0.77% | +0.95% | +17.69% | +51.46% | 189B | |
| +2.36% | +1.38% | +14.80% | +61.34% | 154B | |
| Average | +0.21% | +0.61% | +18.54% | +42.12% | 376.23B | |
| Weighted average by Cap. | -0.30% | -0.24% | +27.43% | +67.12% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 41.94B 444M 382M 352M 331M 621M 627M 4.16B 1.62B 20.54B 1.66B 1.63B 71.17B | 46.45B 491M 423M 390M 366M 687M 695M 4.61B 1.79B 22.75B 1.84B 1.8B 78.83B |
| Net income | 11.4B 121M 104M 95.7M 89.86M 169M 170M 1.13B 441M 5.58B 453M 443M 19.35B | 12.87B 136M 117M 108M 101M 190M 192M 1.28B 497M 6.3B 511M 500M 21.85B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/06/26 | 2,202.80 ₹ | +3.78% | 199,157 |
| 15/06/26 | 2,122.50 ₹ | +0.05% | 162,107 |
| 12/06/26 | 2,121.50 ₹ | +0.87% | 357,494 |
| 11/06/26 | 2,103.20 ₹ | -3.30% | 238,350 |
| 10/06/26 | 2,174.90 ₹ | -0.90% | 68,793 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 500660 Stock
- GLAXO Stock
Select your edition
All financial news and data tailored to specific country editions
